ライフサイエンスコーパス: septic

1 first but increasing as the infection became septic.

2 re of diagnostic value for the prediction of septic acute kidney injury courses requiring renal repla

3 er candidates for the risk stratification of septic acute kidney injury patients with the need for re

4 The primary endpoint was the development of septic acute kidney injury with the need for renal repla

5 In early experimental septic acute kidney injury, fluid bolus therapy transien

6 otential therapeutic strategy for preventing septic AKI.

7 2alpha) axis as a major pathway in mediating septic AKI.

8 of whole blood DNA samples from a cohort of septic and nonseptic critically ill patients.

9 We assessed, in septic and nonseptic ICU patients, the relation between

10 PSP is able to differentiate between septic and nonseptic patients during acute burn care.

11 data from seven external datasets containing septic and nonseptic patients, 81% of the differentially

12 Critically ill septic and nonseptic patients.

13 01), black (100% vs 53%; P < .001), and have septic arthritis (35% vs 1%; P < .001).

14 Native joint septic arthritis (NJSA) is poorly studied.

15 gery for trauma (RR 1.9 [1.4-2.6]), previous septic arthritis (RR 4.9 [2.7-7.6]) or inflammatory arth

16 ins were identified and were associated with septic arthritis among black men who have sex with men a

17 In 10 195 (84%) patients with septic arthritis as the primary admitting diagnosis, 90-

18 s who received arthroscopic knee washout for septic arthritis in England between April 1, 1997, and M

19 system/spine infections, osteomyelitis, and septic arthritis were labeled as IDRIs if discharge code

20 s (infective endocarditis, epidural abscess, septic arthritis, and osteomyelitis), the mean age was 4

21 or infective endocarditis, epidural abscess, septic arthritis, or osteomyelitis.

22 rial extracorporeal membrane oxygenation for septic cardiomyopathy but also indicate improved hospita

23 ks of respiratory, cardiac, anastomotic, and septic complications.

24 clinical outcomes in severe inflammatory and septic conditions.Objectives: Although recent investigat

25 er's patch effector memory CD4(+) T cells in septic CR mice.

26 ease in cells and lipopolysaccharide-induced septic death in mice.

27 Nonetheless, it is noteworthy that an acute septic episode may harbor antitumoral properties under p

28 as a significant predictor for the number of septic episodes (P = 0.02); independent of age, model of

29 sitively associated with EA, while number of septic episodes was negatively associated (HR = 0.95; 95

30 of hyperinflammation frequently camouflages septic events delaying the initiation of targeted intens

31 nto 6 groups (N = 12/group): 3 control and 3 septic groups depending on the euthanasia time (24 h, 48

32 ng pathogenic effectors may benefit the post-septic host.

33 hether these phenotypic similarities between septic humans and mice are replicated at the circulating

34 ting heparan sulfate in endotoxemic mice and septic humans was enriched in 2-O- and N-sulfated disacc

35 isms that may be triggered simultaneously in septic hypertensive patients.

36 ghts the importance of glucose metabolism in septic inflammation.

37 jurisdictions with limited information about septic infrastructure may be able to use geospatial data

38 nd environmental justice concerns related to septic infrastructure.

39 gaster, to investigate how infection through septic injury modulates nutritional intake and how macro

40 The consequences of septic knee arthritis in patients undergoing arthroscopi

41 LPS)-induced systemic inflammation (SI; at a septic-like model) in spontaneously hypertensive rats (S

42 ethod for the real-time, label-free study of septic liver damage.

43 t discrimination between liver sections from septic mice and sham-treated mice in contrast to SHG (AU

44 eatment results in a 100% survival in severe septic mice by controlling both infection and hyperinfla

45 The protective effects of rolipram on septic mice may result from inhibition of the MAP kinase

46 d provides an insight on the contribution of septic mice models in the study of multi organ dysfuncti

47 arkedly decreased in rmCIRP-injected mice or septic mice treated with LP17.

48 In contrast, septic mice treated with LXR antagonist showed increased

49 Septic mice were treated with [(C2S, 3S, 4R)-1-O-(alpha-

50 une network was similar in IRF3-KO versus WT septic mice, although the tempo of connectivity differed

51 o the complete recovery of immunocompromised septic mice.

52 posure significantly improved the outcome of septic mice.

53 the identified IsdA mAbs worked in a murine septic model of infection to reduce bacterial burden dur

54 usive hydrogel resins simultaneously adsorbs septic molecules, e.g. lipopolysaccharides (LPS), cytoki

55 d proinflammatory shift was also observed in septic monocytes, signifying that patients suffering fro

56 k requiring inotropes, and with demonstrable septic myocardial depression.

57 s) following infection with GBS strains from septic neonates or colonized mothers.

58 lop an exhaustive phenotype resembling human septic neutrophils with elevated expression of ICAM1, CD

59 8-5.25) in ICU patients whether admitted for septic or nonseptic causes and 2) the need for renal rep

60 y, we prospectively analyzed PBMCs both from septic patients (n = 10) and lipopolysaccharide stimulat

61 ription initiation complex, was 74% lower in septic patients (p < 0.001).

62 he platelet transcriptome and translatome in septic patients and healthy donors.

63 changes in platelet gene expression between septic patients and mice subjected to CLP.

64 o aid in the rapid and accurate diagnosis of septic patients and to ensure antibiotics are given to p

65 bolic and immune alterations and over 1/3 of septic patients are diabetic, but the mechanism linking

66 Most septic patients are initially encountered in the emergen

67 gnifying a steeper increase in PSP levels in septic patients as opposed to those exhibiting a nonsept

68 of these sulfation patterns in the plasma of septic patients at intensive care unit (ICU) admission p

69 From 256 plasma samples of 48 septic patients at up to seven consecutive time points w

70 Septic patients frequently develop cognitive impairment

71 severity score >= 15) and nonsevere injured septic patients had an odds ratio of 1.39 (95% CI, 1.31-

72 Septic patients had higher severity of illness scores, c

73 A cohort of septic patients had increased cytokine production compar

74 26 studies, compared with healthy controls, septic patients had significantly (p <= 0.05) increased

75 ies, compared with critically ill nonseptic, septic patients had significantly increased checkpoint m

76 ation of serum procalcitonin (PCT) levels in septic patients is facilitated by reviewing the known st

77 onuclear cells were significantly reduced in septic patients on day 1 (p < 0.05), whereas mitochondri

78 More important, neutrophils from septic patients showed increased ABCA1 messenger ribonuc

79 Septic patients who died had early, profound, and sustai

80 We hypothesized that septic patients with bloodstream infections may transiti

81 evaluating the thermoregulatory outcomes of septic patients with hypertension.

82 All adult septic patients with positive blood cultures over a 7-ye

83 All adult septic patients with positive blood cultures over a peri

84 -based forms of research in order to improve septic patients' morbidity and mortality.

85 contribute to the high mortality rates among septic patients, despite new antimicrobials and resuscit

86 In septic patients, plasma concentrations of interleukin (I

87 been considerable effort to immunophenotype septic patients, these methods have often not accurately

88 L-7 restored ex vivo IFN-gamma production in septic patients.

89 en in control, critically ill nonseptic, and septic patients.

90 ry rate <0.05) transcripts in platelets from septic patients.

91 that did not mimic the metabolic settings of septic patients.

92 n guide duration of antibacterial therapy in septic patients.

93 increased checkpoint molecule expression in septic patients.

94 vere Sepsis and Septic Shock-1) enrolled 583 septic patients.

95 of the peritoneum capable of neutralizing a septic polymicrobial insult.

96 ate the expression of TLR 2, 3, 4 and 7 in a septic process.

97 -day mortality decreased among patients with septic shock (22.1% to 15.5%), septic shock with acute r

98 5% male; mean +/- SD, 60 +/- 14 yr old) with septic shock (30%), hemorrhagic shock (15%), cardiogenic

99 10.3%), severe sepsis (20.3% vs 10.3%), and septic shock (33.5% vs 15.9%) was higher in prolonged ac

100 most costly complications were postoperative septic shock (4.0-fold, 95% CI 3.58-4.43) renal insuffic

101 nd chemotherapy (94 patients) were sepsis or septic shock (46 patients [19%] for quizartinib vs 18 [1

102 R had the best discrimination for predicting septic shock (c-statistic 0.90), respiratory failure req

103 The cohorts consisted of 120 patients with septic shock (cohort 1) and 88 patients with S. aureus b

104 rvival benefit was observed in patients with septic shock (HR, 0.80 [CI, .26-2.46]), in NVIE (HR, 0.7

105 ified complications were hepatitis (n = 36), septic shock (n = 22), and pulmonary complications/pneum

106 e ICU admission (OR 5.07, 95% CI 3.18-8.07), septic shock (OR 1.92, 95% CI 0.93-3.98), corticosteroid

107 ST16 (OR 21.4; CI95% 2.3-202.8; p=0,008) and septic shock (OR 11.9; CI95% 4.2-34.1; p<0,001) were ind

108 R 1.943; 95% CI 1.209-3.123), development of septic shock (OR 25.896; 95% CI 8.970-74.765), and the p

109 ence interval [CI], 2.3-202.8; P = .008) and septic shock (OR, 11.9; 95% CI, 4.2-34.1; P < .001) were

110 able intensive care patients with or without septic shock (recommended threshold for RBC transfusion,

111 met consensus criteria for severe sepsis or septic shock (reference standard cohort).

112 ation of fluid for infants and children with septic shock (this latter topic was evaluated by evidenc

113 Septic shock 48-hour, 3-14-day and greater than 14-day m

114 HLA-A02:01 was associated with lower odds of septic shock [OR 0.52, (0.32-0.82)].

115 fected patients: 1) patients in the ICU with septic shock and 2) hospitalized patients with Staphyloc

116 hours and first 24 hours after the onset of septic shock and 30-day in-hospital mortality; 2) determ

117 id Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids

118 id Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids

119 its potential as a driver of inflammation in septic shock and autoimmune diseases, GSDMD represents a

120 We then analyze plasma from patients with septic shock and find that increasing levels of IL-6 and

121 id Treatment in Critically Ill Patients with Septic Shock and hydrocortisone at a 50 mg IV bolus ever

122 we validated the known genes and pathways in septic shock and identified the unexplored septic shock-

123 o validate this association in children with septic shock and in a juvenile murine model of sepsis.

124 irculating endothelial progenitor cells from septic shock and nonseptic shock patients showed evidenc

125 s in the durvalumab plus tremelimumab group (septic shock and pneumonitis), and one (<1%) patient in

126 ccurred in one patient in the placebo group (septic shock and pulmonary oedema) and one patient in th

127 Patients with septic shock and S. aureus bacteremia admitted directly

128 ient avoided cost was multiplied by expected septic shock annual incidence.

129 Critically ill patients with sepsis or septic shock are at an increased risk of death.

130 outcomes in patients with severe sepsis and septic shock as a result of the full implementation of t

131 of vasopressin infusion among patients with septic shock as well as vasoplegic shock after cardiotho

132 ally ventilated, and 42% in severe sepsis or septic shock at infection onset.

133 nter this state are highly likely to develop septic shock at some future time.

134 ration of HAT therapy among U.S. adults with septic shock before and after study publication and to c

135 Septic shock carries a high mortality risk.

136 a 6-hour resuscitation in 688 patients with septic shock enrolled in the ProCESS trial.

137 d 12 months following PICU admission for the septic shock event, 8%, 11%, 12%, and 13% of patients ha

138 randomized controlled trials in the field of septic shock failed to demonstrate a benefit on mortalit

139 btained serum samples from 529 patients with septic shock from 22 ICUs in Australia and New Zealand.M

140 A total of 361,323 severe sepsis or septic shock hospital discharges were included.

141 revealed the role of caspase-11 in mediating septic shock in response to lethal doses of lipopolysacc

142 a central mediator of systemic inflammation, septic shock in the Plasmodium chabaudi-infected mice an

143 logic studies of pediatric severe sepsis and septic shock in this large, multicenter database.

144 pective observational study of children with septic shock in whom the PERSEVERE biomarkers were measu

145 Septic shock is a life-threatening condition in which ti

146 Septic shock is a systemic inflammation associated with

147 Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evalua

148 Septicemia with septic shock is the most common cause of death, with mor

149 Studies have indicated that patients with septic shock may benefit from extracorporeal membrane ox

150 ntial Organ Failure Assessment scores in the septic shock nonsurvivors patients but not in nonseptic

151 In this study, we demonstrate that in septic shock O-GlcNAc stimulation improves global animal

152 ting consensus criteria for severe sepsis or septic shock on manual chart review were entered into th

153 r patients admitted to the ICU for sepsis or septic shock over the last 2 decades.

154 Circulating endothelial cells from septic shock patients are acutely converted into fibrobl

155 Sepsis and septic shock patients had higher maximum ferritin levels

156 he timing of antibiotics and mortality among septic shock patients has not been examined among patien

157 mean arterial pressure with noradrenaline in septic shock patients improves density and flow in small

158 ng samples from 10 healthy volunteers and 20 septic shock patients stratified using human leukocyte a

159 es: healthy volunteers, intermediate mHLA-DR septic shock patients, and low mHLA-DR septic shock pati

160 erbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response.

161 (TNF-alpha) secretion by single monocytes in septic shock patients, to study immune responses by meas

162 allogeneic mesenchymal stem/stromal cells in septic shock patients.

163 mass might be a useful prognostic factor for septic shock patients.

164 LA-DR septic shock patients, and low mHLA-DR septic shock patients.

165 ts (n = 274) diagnosed with severe sepsis or septic shock per Sepsis-2 criteria from September to Nov

166 e in insured patients with severe sepsis and septic shock post Affordable Care Act.

167 Among patients with septic shock receiving norepinephrine, administration of

168 hepatitis related to atezolizumab [n=1] and septic shock related to nab-paclitaxel [n=1]) and one (<

169 hypotensive and was admitted to ICU in frank septic shock requiring inotropes, and with demonstrable

170 Abnormal peripheral perfusion after septic shock resuscitation has been associated with orga

171 sus Norepinephrine Infusion in Patients With Septic Shock studies (n=632).

172 nd Simplified Acute Physiology Score II with septic shock survivors (unexposed group).

173 howed discriminatory power between pediatric septic shock survivors and nonsurvivor types.

174 t GNB had a significantly lower incidence of septic shock than nontransplant GNB (10.3% vs 30.7%, p =

175 epsis who are at elevated risk of developing septic shock therefore has the potential to save lives b

176 all group of patients with severe sepsis and septic shock treated with hydrocortisone, high-dose asco

177 In 632 patients enrolled in Vasopressin and Septic Shock Trial, Proprotein Convertase Subtilisin/Kex

178 ped patients enrolled in the Vasopressin and Septic Shock Trial.

179 patients with AKI in VASST (Vasopressin and Septic Shock Trial; n = 271), and differences in treatme

180 ated Protein C and Corticosteroids for Human Septic Shock trials.

181 organ support-free days outcome reporting in septic shock trials.

182 ated Protein C and Corticosteroids for Human Septic Shock trials.

183 re initiating therapy, whereas patients with septic shock warrant emergent broad-spectrum antibiotics

184 ng intensity during the first 24 hours after septic shock was associated with increased mortality.

185 Transcriptomic profile at onset of septic shock was associated with response to corticoster

186 Septic shock was the main reason for admission mostly of

187 ncer patients admitted to ICUs for sepsis or septic shock were extracted from the Groupe de Recherche

188 f 506 patients with S. aureus bacteremia and septic shock were included in the analysis.

189 reviewed prospectively enrolled registry of septic shock which had 817 consecutive patients.

190 tcomes of 82 patients (aged >=18 years) with septic shock who received VA-ECMO at five academic ECMO

191 Two deaths were deemed treatment related (septic shock with 60 mg/m(2); pneumonia with 90 mg/m(2))

192 ong all groups (septic shock: 12.6% to 6.7%; septic shock with acute respiratory failure receiving in

193 patients with septic shock (22.1% to 15.5%), septic shock with acute respiratory failure receiving in

194 Cure of severe infections, sepsis, and septic shock with antimicrobial drugs is a challenge bec

195 kers can identify subgroups of patients with septic shock with differential treatment responses to hy

196 Hospital survival was 90% for septic shock with left ventricular failure and 64.7% in

197 He was in a septic shock with multiple organ failure up on presentat

198 predict mortality and rate of recovery from septic shock with over 90% accuracy.

199 id Treatment in Critically Ill Patients with Septic Shock) and $30,911 (Activated Protein C and Corti

200 complication of atrial fibrillation and one septic shock) and two due to disease progression.

201 ated Protein C and Corticosteroids for Human Septic Shock) per patient.

202 oclax group (two from pneumonia and one from septic shock) were considered treatment-related; no deat

203 equiring intensive care and/or patients with septic shock), blending together mortality estimates fro

204 t failure, sepsis severity (severe sepsis vs septic shock), obesity, Mortality in Emergency Departmen

205 Three months following septic shock, 346 of 389 subjects (88.9%) were alive and

206 without the characteristic) are as follows: septic shock, 7.27 (7.19-7.35); metastatic cancer and ac

207 id Treatment in Critically Ill Patients with Septic Shock, adjunctive hydrocortisone therapy showed a

208 ated Protein C and Corticosteroids for Human Septic Shock, adjunctive hydrocortisone therapy showed a

209 groups have a 76.5% and 10.4% prevalence of septic shock, and 43% and 18% mortality, respectively.

210 severity score 33); 33% developed sepsis, 6% septic shock, and in-hospital mortality was 14%.

211 LPS can cause death as a result of septic shock, and its lipid A core is the target of poly

212 zyme inhibitors had a higher risk of sepsis, septic shock, and mortality than those receiving angiote

213 hemophagocytic lymphohistiocytosis, sepsis, septic shock, and other conditions were distinctly diffe

214 hemophagocytic lymphohistiocytosis, sepsis, septic shock, and other diagnoses.

215 on score, LogEuroSCORE, acute heart failure, septic shock, and paravalvular complications were risk f

216 the trials were performed in the setting of septic shock, and the most frequent comparator was a com

217 sepsis inpatient admission remain high: for septic shock, approximately 60%; for severe sepsis, appr

218 ng patients with sepsis who will progress to septic shock, as defined by Sepsis- 3 criteria, with the

219 ided resuscitation strategy in patients with septic shock, but the difference in the primary outcome,

220 Cardiogenic and septic shock, cardiac arrhythmia, and postsurgical compl

221 nting to the emergency department with early septic shock, early goal-directed therapy compared with

222 nal capillary density and/or RBC velocity in septic shock, heart failure, hypovolemia, obstructive sh

223 s for all patients with suspected sepsis and septic shock, ideally within 1 hour of recognition.

224 repinephrine, the first-line vasopressor for septic shock, is not always effective and has important

225 Further, septic shock, late-onset cardiac dysfunction, and multio

226 osis and prognosis of acute ischemic stroke, septic shock, lung injuries, insulin resistance in diabe

227 ephrine, the cornerstone vasopressor used in septic shock, may contribute to immune dysregulation and

228 he chlorambucil plus obinutuzumab group (n=1 septic shock, n=1 metastatic skin squamous carcinoma).

229 Among patients with early septic shock, receipt of HAT was not associated with mor

230 four clusters following early prediction of septic shock, stratifying by outcome: the highest-risk a

231 In patients with septic shock, the combination of ascorbic acid, corticos

232 0.92-0.98).Conclusions: Among children with septic shock, the PERSEVERE biomarkers predict severe D(

233 acid were not.Conclusions: In patients with septic shock, there was no heterogeneity in effect of ad

234 In septic shock, thrombocytopenia is associated with increa

235 ntensive care unit (ICU) stay for >24 hours, septic shock, vasoactive agents, positive-pressure venti

236 In patients with early septic shock, we compared the association of early HAT t

237 enomedullin and Outcome in Severe Sepsis and Septic Shock-1) enrolled 583 septic patients.

238 n septic shock and identified the unexplored septic shock-related genes and functional groups.

239 for children encountering community-acquired septic shock.

240 t least 1 year following hospitalization for septic shock.

241 the development of post-traumatic sepsis and septic shock.

242 f this combination therapy for patients with septic shock.

243 icated course and mortality in children with septic shock.

244 onth 3 follow-up among children encountering septic shock.

245 may be for patients with suspected sepsis or septic shock.

246 ts a potential new data-driven definition of septic shock.

247 gy Score 2: 54 +/- 20), 53 (54%) experienced septic shock.

248 life disability among children encountering septic shock.

249 Critical Sepsis, was defined, approximating septic shock.

250 coverage to any patient suspected of having septic shock.

251 acterial clearance in the juvenile host with septic shock.

252 ion is detrimental to the juvenile host with septic shock.

253 ong children encountering community-acquired septic shock.

254 ovascular and endothelial alterations during septic shock.

255 omputing risk of transition from sepsis into septic shock.

256 e improved hospital survival in distributive septic shock.

257 ing missed 66 patients with severe sepsis or septic shock.

258 3%), patients had more liver dysfunction and septic shock.

259 s better for patients with severe sepsis and septic shock.

260 enues for a potential therapy of early-stage septic shock.

261 nd incidence of thrombocytopenia are high in septic shock.

262 PS is critical for antibacterial defense and septic shock.

263 y been proposed to confer protection against septic shock.

264 to improve outcomes in cancer patients with septic shock.

265 in development and progression of pediatric septic shock.

266 ine or vasopressin, or to corticosteroids in septic shock.

267 omidine may decrease norepinephrine doses in septic shock.

268 he impending occurrence of severe sepsis and septic shock.

269 ity to adverse outcomes including sepsis and septic shock.

270 a total of 150,845 visits for severe sepsis/septic shock.

271 se, we believe, represents the true onset of septic shock.

272 mortality in children with severe sepsis or septic shock.

273 ECMO) obtained from three large databases of septic shock.

274 s been identified as a potential therapy for septic shock.

275 ent in 28% of children with severe sepsis or septic shock.

276 thiamine vs placebo for adult patients with septic shock.

277 e followed for the development of sepsis and septic shock.

278 antibiotic administration for patients with septic shock.

279 enetic factors and post-traumatic sepsis and septic shock.

280 cytokines was assessed in 195 patients with septic shock.Measurements and Main Results: Norepinephri

281 ated AKI on Day 3 (D(3) SA-AKI) in pediatric septic shock.Methods: We performed secondary analysis of

282 stimate baseline mortality risk in pediatric septic shock.Objectives: To assess the association betwe

283 ty after 14 days decreased among all groups (septic shock: 12.6% to 6.7%; septic shock with acute res

284 nical Modification code for severe sepsis or septic shock; 3,021 of these patients (28%) had an immun

285 Among this recent cohort of 301 septic SICU patients, 30-day mortality was 9.6%.

286 s, 38% of the fertilizer sources, 51% of the septic sources, 98% of the atmospheric deposition to the

287 is in systemic viral infections can induce a septic state with leaky capillary syndrome, disseminated

288 Across 12 studies, compared with septic survivors, nonsurvivors had significantly increas

289 ate wells studied, suggesting that household septic systems are the source of this contamination.

290 lity in microbial contamination, the role of septic systems as sources of contamination, and the effe

291 hree wells confirmed the impact of household septic systems on well contamination.

292 grances), sewage treatment techniques (e.g., septic systems), and ecosystem types (e.g., lakes).

293 site waste treatment systems (OWTS), such as septic systems, present to human health and the environm

294 ewers connecting several toilets to communal septic tanks (3-5 USD/person/year).

295 In 3 gram-negative septic transfusion cases, we performed metagenomic next-

296 In three Gram-negative septic transfusion cases, we performed mNGS of direct cl

297 Investigating septic transfusion events is often restricted by the lim

298 Investigation of septic transfusion events is often restricted by the lim

299 therapeutic opportunity for the treatment of septic vascular leakage.

300 e also performed subgroup analyses comparing septic with nonseptic patients.